Clinical Research

RSS icon

Confirmed: AFib ablation more beneficial for patients with HFrEF than those with HFpEF

Researchers explored data from nearly 2,500 AFib ablation patients, sharing their findings in JAMA Cardiology.

An 86-year-old patient is showing signs of improvement six months after receiving the world’s first implant of a new-look medical device for treating tricuspid regurgitation (TR), according to new data published in JACC: Cardiovascular Interventions.[1] The device in question, the Tricuspid Flow Optimizer, was developed by Triflo Cardiovascular, a U.S.-based biomedical company founded in 2017 by a team of structural heart specialists.

Cardiologists share update after world’s first implant of new optimizer device for tricuspid regurgitation

The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.

Thumbnail

Could diamond dust replace gadolinium in MRI contrast agents?

An accidental discovery could have future implications for the material makeup for MRI contrast media.

Thumbnail

Statin therapy may help HFpEF patients lower their risk of death, heart attack or stroke

All participants were free of ASCVD and had no history of statin use at the start of the study. 

Multiple sclerosis ribbon MS

New PET technique spots 'smoldering' changes not visible on MRI in the brains of MS patients

The new technique uncovers hidden inflammation in patients who, despite undergoing extensive treatment for the condition, had worsening symptoms.

old elderly couple coffee drink retired love romance man

TAVR, SAVR linked to similar QOL improvements for intermediate-risk patients after five years

TAVR was initially associated with greater benefits than surgery, but that difference faded by the end of the first year.

virtual reality surgical planning

Rad techs helpfully ‘stand in a surgeon’s shoes’ thanks to virtual reality

Johns Hopkins researchers demonstrated the worthiness of the concept this year.

Video of James Januzzi explaining the results of a new diabetic cardiomyopathy treatment in ACC 2024 late-breaking ARISE-HF trial. #ACC #ACC24 #ACC2024

Diabetic cardiomyopathy treatment shows promise in ARISE-HF

James Januzzi Jr., MD, said the treatment's overall impact was neutral, but he and his team saw "a very clear and encouraging signal."

Displaying 185 - 192 of 765
Design by Adaptive Theme